At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses novel therapeutic combinations that are currently being investigated in the clinic to address the unmet need in mantle cell lymphoma treatment. These therapeutic agents include bortezomib, lenalidomide, ibrutinib and rituximab.
This programme has been supported by sponsorship from Celgene
Advertisement